Proliferative diabetic retinopathy
Conditions
Interventions
Period: 6 months follow up after intravitreal bevacizumab (Avastin) injection for preoperative adjunct therapy. Dose: Bevacizumab(Avastin) 0.16mg/0.05 ml Repeat: Single time
Period: 6 months follow
Sponsors
Division of Ophthalmology, Department of Visual Sciences, Surugadai-Hospital, Nihon University.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with proliferative diabetic retinopathy who are indicated for vitrectomy.
Exclusion criteria
Exclusion criteria: Patients who had undergone intraocular surgery or retinal photocoagulation within 6 months before the study, and those who had undergone intravitreal injection of drugs or sub-Tenon injection of steroids within 6 months before the study were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Preoperative vitreous VEGF concentration, Number of intraoperative coagulation spots, Number of reoperation caused by recurent postoperative hemorrhage, Post operative Visual acuity, operation time, Kind of tamponade after operation, Number of intrapoerative photocoagulation | — |
Secondary
| Measure | Time frame |
|---|---|
| VEGF concentrations in vitreous, surgical time, frequencies of using gas and silicon oil temponade, number of intraoperative laser treatment, frequency of iatrogenic retinal breaks, postoperative (1 month) visual acuity, visual improvement. | — |
Countries
Japan
Contacts
Public ContactAyumu Manabe
Surugadai-Hospital, Nihon University Division of Ophthalmology, Department of Visual Sciences
Outcome results
None listed